Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Laban

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Journal for Immunotherapy of Cancer|September 8, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancerCaroline Even, Kevin J Harrington, Erminia Massarelli, et al.
Neoplasia (New York, N.Y.)|January 17, 2024
Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trialMarkus Hecht, Benjamin Frey, Udo S Gaipl, et al.
Cancer Research Communications|February 8, 2024
INHBA is Enriched in HPV-negative Oropharyngeal Squamous Cell Carcinoma and Promotes Cancer ProgressionTsima Abou Kors, Linda Hofmann, Annika Betzler, et al.
Journal for Immunotherapy of Cancer|January 26, 2022
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancerMarkus Hecht, Markus Eckstein, Sandra Rutzner, et al.
Head & Neck|April 16, 2016
Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypesIndu Varier, Brieze R Keeley, Rosemarie Krupar, et al.
Cancers|January 8, 2023
BTK Isoforms p80 and p65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor ProgressionAnnika C Betzler, Hannah Strobel, Tsima Abou Kors, et al.
Nature Medicine|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
British Journal of Cancer|February 24, 2023
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccinationLena Mühlenbruch, Tsima Abou-Kors, Marissa L Dubbelaar, et al.
Nature Medicine|June 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Frontiers in Immunology|August 13, 2024
Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigensTsima Abou Kors, Matthias Meier, Lena Mühlenbruch, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Journal for Immunotherapy of Cancer|September 8, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancerCaroline Even, Kevin J Harrington, Erminia Massarelli, et al.
Neoplasia (New York, N.Y.)|January 17, 2024
Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trialMarkus Hecht, Benjamin Frey, Udo S Gaipl, et al.
Cancer Research Communications|February 8, 2024
INHBA is Enriched in HPV-negative Oropharyngeal Squamous Cell Carcinoma and Promotes Cancer ProgressionTsima Abou Kors, Linda Hofmann, Annika Betzler, et al.
Journal for Immunotherapy of Cancer|January 26, 2022
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancerMarkus Hecht, Markus Eckstein, Sandra Rutzner, et al.
Head & Neck|April 16, 2016
Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypesIndu Varier, Brieze R Keeley, Rosemarie Krupar, et al.
Cancers|January 8, 2023
BTK Isoforms p80 and p65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor ProgressionAnnika C Betzler, Hannah Strobel, Tsima Abou Kors, et al.
Nature Medicine|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
British Journal of Cancer|February 24, 2023
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccinationLena Mühlenbruch, Tsima Abou-Kors, Marissa L Dubbelaar, et al.
Nature Medicine|June 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Frontiers in Immunology|August 13, 2024
Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigensTsima Abou Kors, Matthias Meier, Lena Mühlenbruch, et al.
Pageof 10